German Doctors Seek

4 June 1995

End To Seehofer Reforms

The federation of German panel doctors has called for an end to the health service cost-control and reform regime, and urged the Bonn coalition government to keep its promise and allow the regime to expire at the end of 1995. Speakers at the federation assembly in Stuttgart stressed their commitment to economic use of treatments but rejected a state-controlled spending budget.

The health funds have meanwhile urged the doctors to enter talks about regional budgeting to control drug spending, on the assumption that the regime will end in december. And the drug industry association, the BPI, says a large number of drug firms will face major problems if the new positive list is introduced in the form recommended by the funds. A survey among the BPI's 350 member companies, with 131 responding, showed that 40% of companies stood to lose over 60% of current sales. Total sales volume affected would be about 2.3 billion Deutschemarks ($1.6 billion), according to the BPI.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight